Published in Lancet on June 27, 1992
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54
Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96
Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum. Proc Natl Acad Sci U S A (1996) 4.70
Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32
Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29
Tolerogenic immunosuppression for organ transplantation. Lancet (2003) 4.09
Baboon-to-human liver transplantation. Lancet (1993) 4.01
Antigen localization and migration in immunity and tolerance. N Engl J Med (1998) 3.71
Systemic chimerism in human female recipients of male livers. Lancet (1992) 3.63
Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63
Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med (1993) 3.36
Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation (1993) 3.13
Outcome analysis of 71 clinical intestinal transplantations. Ann Surg (1995) 2.95
The lost chord: microchimerism and allograft survival. Immunol Today (1996) 2.81
Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc (1993) 2.81
Propagation of dendritic cell progenitors from normal mouse liver using granulocyte/macrophage colony-stimulating factor and their maturational development in the presence of type-1 collagen. J Exp Med (1994) 2.48
Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31
Three years clinical experience with intestinal transplantation. J Am Coll Surg (1994) 2.20
Transplantation milestones. Viewed with one- and two-way paradigms of tolerance. JAMA (1995) 2.20
Transplantation tolerance from a historical perspective. Nat Rev Immunol (2001) 2.04
Successful hamster-to-rat liver xenotransplantation under FK506 immunosuppression induces unresponsiveness to hamster heart and skin. Transplantation (1993) 1.94
Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg (2005) 1.93
Growth of donor-derived dendritic cells from the bone marrow of murine liver allograft recipients in response to granulocyte/macrophage colony-stimulating factor. J Exp Med (1995) 1.88
Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation (1996) 1.86
Microchimerism, dendritic cell progenitors and transplantation tolerance. Stem Cells (1995) 1.83
Apoptosis within spontaneously accepted mouse liver allografts: evidence for deletion of cytotoxic T cells and implications for tolerance induction. J Immunol (1997) 1.81
The saga of liver replacement, with particular reference to the reciprocal influence of liver and kidney transplantation (1955-1967). J Am Coll Surg (2002) 1.81
Transplantation tolerance, microchimerism, and the two-way paradigm. Theor Med Bioeth (1998) 1.67
Multilineage hematopoietic reconstitution of supralethally irradiated rats by syngeneic whole organ transplantation. With oarticular reference to the liver. Transplantation (1996) 1.65
Bone marrow-derived dendritic cell progenitors (NLDC 145+, MHC class II+, B7-1dim, B7-2-) induce alloantigen-specific hyporesponsiveness in murine T lymphocytes. Transplantation (1995) 1.63
Immunosuppression for liver transplantation in HCV-infected patients: mechanism-based principles. Liver Transpl (2005) 1.61
Incidence and risk factors associated with the development of cytomegalovirus disease after intestinal transplantation. Transplantation (1995) 1.59
Weaning of immunosuppression in long-term liver transplant recipients. Transplantation (1995) 1.59
Weaning of immunosuppression in liver transplant recipients. Transplantation (1997) 1.57
The biological basis of and strategies for clinical xenotransplantation. Immunol Rev (1994) 1.56
Immunomodulation for intestinal transplantation by allograft irradiation, adjunct donor bone marrow infusion, or both. Transplantation (2000) 1.53
The site of primary T cell activation is a determinant of the balance between intrahepatic tolerance and immunity. J Clin Invest (2004) 1.53
Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg (2003) 1.52
Split tolerance induced by orthotopic liver transplantation in mice. Transplantation (1994) 1.52
Drug development and testing in relation to cell migration and chimerism. Transplant Proc (1993) 1.52
Granulocyte/macrophage colony-stimulating factor-stimulated hepatic dendritic cell progenitors prolong pancreatic islet allograft survival. Transplantation (1995) 1.51
Clinical intestinal transplantation: a decade of experience at a single center. Ann Surg (2001) 1.44
Analysis of chronic rejection and obliterative arteriopathy. Possible contributions of donor antigen-presenting cells and lymphatic disruption. Am J Pathol (1997) 1.41
Abdominal multivisceral transplantation. Transplantation (1995) 1.37
Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation. J Pediatr (2006) 1.36
Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression. Ann Surg (1994) 1.33
The current status of small bowel transplantation in the UK and internationally. Gut (2005) 1.31
Spontaneous and iatrogenically augmented leukocyte chimerism in organ transplant recipients. Transplant Proc (1994) 1.29
Simultaneous administration of adjuvant donor bone marrow in pancreas transplant recipients. Ann Surg (1999) 1.24
Augmentation of chimerism in whole organ recipients by simultaneous infusion of donor bone marrow cells. Transplant Proc (1995) 1.24
Dendritic cells and immune regulation in the liver. Gut (2003) 1.19
Combined kidney/bone marrow transplantation--evidence of augmentation of chimerism. Transplantation (1995) 1.19
Immune status of recipients following bone marrow-augmented solid organ transplantation. Transplantation (1995) 1.18
Isolation, phenotype, and allostimulatory activity of mouse liver dendritic cells. Transplantation (1994) 1.16
Fluorescence in situ hybridization for the Y-chromosome can be used to detect cells of recipient origin in allografted hearts following cardiac transplantation. Am J Pathol (1993) 1.13
Microchimerism maintains deletion of the donor cell-specific CD8+ T cell repertoire. J Clin Invest (2006) 1.13
Dendritic cell replacement in long-surviving liver and cardiac xenografts. Transplantation (1993) 1.10
Graft-versus-host disease after liver and small bowel transplantation in a child. Clin Transplant (1997) 1.09
Frequent achievement of a drug-free state after orthotopic liver transplantation. Transplant Proc (1993) 1.08
Donor and recipient leukocytes in organ allografts of recipients with variable donor-specific tolerance: with particular reference to chronic rejection. Liver Transpl (2000) 1.07
Augmentation of chimerism with perioperative donor bone marrow infusion in organ transplant recipients: a 44 month follow-up. Transplant Proc (1997) 1.07
Chimerism and tolerance in transplantation. Proc Natl Acad Sci U S A (2004) 1.07
Progress in renal transplantation. A single center study of 3359 patients over 25 years. Ann Surg (1995) 1.07
Human pancreatic islet-derived progenitor cell engraftment in immunocompetent mice. Am J Pathol (2004) 1.07
In vitro propagation and homing of liver-derived dendritic cell progenitors to lymphoid tissues of allogeneic recipients. Implications for the establishment and maintenance of donor cell chimerism following liver transplantation. Transplantation (1995) 1.06
Humoral and cellular immunopathology of hepatic and cardiac hamster-into-rat xenograft rejection. Marked stimulation of IgM++bright/IgD+dull splenic B cells. Am J Pathol (1993) 1.06
Progenitor cells from the explanted heart generate immunocompatible myocardium within the transplanted donor heart. Circ Res (2009) 1.06
Epstein-Barr virus, infectious mononucleosis, and posttransplant lymphoproliferative disorders. Transplant Sci (1994) 1.06
Pancreatic islet production of murine interleukin-10 does not inhibit immune-mediated tissue destruction. J Clin Invest (1994) 1.05
Challenges to achieving clinical transplantation tolerance. J Clin Invest (2001) 1.03
Intestinal transplantation in children under FK 506 immunosuppression. J Pediatr Surg (1993) 1.02
Combined bone marrow and whole organ transplantation from the same donor. Transplant Proc (1994) 1.02
Neutrophilic granulocytes are the predominant cell type infiltrating pancreatic islets in contact with ABO-compatible blood. Clin Exp Immunol (2005) 1.01
Bone marrow augmentation for heart, liver, and small bowel transplantation: prolongation of graft survival and incidence of graft-versus-host disease. Transplant Proc (1995) 1.00
Alpha-1-antitrypsin deficiency: current concepts. Lung (2007) 1.00
Rejection of human intestinal allografts: alone or in combination with the liver. Transplant Proc (1994) 0.99
Perioperative donor bone marrow infusion augments chimerism in heart and lung transplant recipients. Ann Thorac Surg (1995) 0.98
Combined simultaneous kidney/bone marrow transplantation. Transplantation (1995) 0.98
Themes of liver transplantation. Hepatology (2010) 0.98
Acquired immunologic tolerance: with particular reference to transplantation. Immunol Res (2007) 0.97
Vascularized bone marrow transplantation in rats: evidence for amplification of hematolymphoid chimerism and freedom from graft-versus-host reaction. Transplant Proc (1995) 0.97
Pattern of graft- and host-specific MHC class II expression in long-term murine cardiac allografts: origin of inflammatory and vascular wall cells. Am J Pathol (1998) 0.96
The politics of grafting cadaver kidneys. Lancet (1996) 0.95
Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: long-term follow-up and evaluation of features for histopathological staging. Transplantation (2000) 0.95
Intestinal transplantation under tacrolimus monotherapy after perioperative lymphoid depletion with rabbit anti-thymocyte globulin (thymoglobulin). Am J Transplant (2005) 0.95
Lessons of organ-induced tolerance learned from historical clinical experience. Transplantation (2004) 0.94
The unfinished legacy of liver transplantation: emphasis on immunology. Hepatology (2006) 0.93
Composite tissue transplantation: a rapidly advancing field. Transplant Proc (2008) 0.92
Human dendritic cells and transplant outcome. Transplantation (2008) 0.92
Risks and benefits of weaning immunosuppression in liver transplant recipients: long-term follow-up. Transplant Proc (1997) 0.92
Explanation for loss of the HLA matching effect. Transplant Proc (1995) 0.91
Adoptive transfer of unresponsiveness to allogeneic skin grafts with hepatic gamma delta + T cells. Immunology (1994) 0.91
Outcome after steroid withdrawal in renal transplant patients receiving tacrolimus-based immunosuppression. Transplant Proc (1998) 0.91
Temporary withdrawal of immunosuppression for life-threatening infections after liver transplantation. Transplantation (1994) 0.91
History of clinical transplantation. World J Surg (2000) 0.91
Recurrent hepatitis C in liver allografts: prospective assessment of diagnostic accuracy, identification of pitfalls, and observations about pathogenesis. Am J Surg Pathol (2004) 0.91
Augmentation of natural chimerism with donor bone marrow in orthotopic liver recipients. Transplant Proc (1996) 0.90
Four-color flow cytometric analysis of peripheral blood donor cell chimerism. Hum Immunol (2003) 0.89
The dendritic cell system and its role in immunogenicity. Annu Rev Immunol (1991) 23.09
Actively acquired tolerance of foreign cells. Nature (1953) 19.82
THE REVERSAL OF REJECTION IN HUMAN RENAL HOMOGRAFTS WITH SUBSEQUENT DEVELOPMENT OF HOMOGRAFT TOLERANCE. Surg Gynecol Obstet (1963) 8.04
The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89
Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. Cell (1990) 6.33
Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92
Induction of immunological tolerance by porcine liver allografts. Nature (1969) 5.89
Progress in and deterrents to orthotopic liver transplantation, with special reference to survival, resistance to hyperacute rejection, and biliary duct reconstruction. Transplant Proc (1974) 5.53
Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells. J Exp Med (1982) 5.09
Demonstration and characterization of Ia-positive dendritic cells in the interstitial connective tissues of rat heart and other tissues, but not brain. J Exp Med (1981) 5.00
Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96
Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature (1984) 4.26
Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85
Induction of specific tissue transplantation tolerance using fractionated total lymphoid irradiation in adult mice: long-term survival of allogeneic bone marrow and skin grafts. J Exp Med (1977) 3.48
Studies of homograft sex and of gamma globulin phenotypes after orthotopic homotransplantation of the human liver. Surg Forum (1969) 2.80
Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59
Soluble HLA antigens in the circulation of liver graft recipients. Transplantation (1989) 2.48
Liver transplantation for type IV glycogen storage disease. N Engl J Med (1991) 2.31
Isohemagglutinins of graft origin after ABO-unmatched liver transplantation. N Engl J Med (1984) 2.25
FK506 suppression of heart and liver allograft rejection. II: The induction of graft acceptance in rats. Transplantation (1990) 2.13
Immunization with skin isografts taken from tolerant mice. Science (1967) 2.05
Lymphocyte traffic and graft-versus-host disease after fully allogeneic small bowel transplantation. Transplant Proc (1991) 1.89
Activation of transplant immunity: effect of donor leukocytes on thyroid allograft rejection. Science (1976) 1.80
Early events in liver allograft rejection. Delineation of sites of simultaneous intragraft and recipient lymphoid tissue sensitization. Am J Pathol (1991) 1.78
Prolongation of murine islet allograft survival by pretreatment of islets with antibody directed to Ia determinants. Proc Natl Acad Sci U S A (1981) 1.77
Interactions between bronchoalveolar lymphocytes and macrophages in heart-lung transplant recipients. Hum Immunol (1985) 1.65
Histocompatibility and liver transplant outcome. Does HLA exert a dualistic effect? Transplantation (1988) 1.61
Donor dendritic cells after liver and heart allotransplantation under short-term immunosuppression. Lancet (1992) 1.61
Medawar's legacy to cellular immunology and clinical transplantation: a commentary on Billingham, Brent and Medawar (1956) 'Quantitative studies on tissue transplantation immunity. III. Actively acquired tolerance'. Philos Trans R Soc Lond B Biol Sci (2015) 1.40
Class I transplantation antigens in solution in body fluids and in the urine. Individuality signals to the environment. J Exp Med (1988) 1.39
Post transplantation donor-specific bone marrow transfusion in polyclonal antilymphocyte serum-treated recipients: the optimal cellular antigen for induction of unresponsiveness to organ allografts. Transplant Proc (1988) 1.38
Prolonged survival of actively enhanced rat renal allografts despite accelerated cellular infiltration and rapid induction of both class I and class II MHC antigens. J Exp Med (1987) 1.34
The transplantation of normal tissues: with special reference to auto- and homotransplants of thyroid and spleen in the anterior chamber of the eye, and subcutaneously, in guinea-pig. Philos Trans R Soc Lond B Biol Sci (1950) 1.33
Donor dendritic cell repopulation in recipients after rat-to-mouse bone-marrow transplantation. Lancet (1992) 1.32
Why are lung allografts more vigorously rejected than hearts? J Heart Transplant (1987) 1.26
National allocation of cadaveric kidneys by HLA matching. Projected effect on outcome and costs. N Engl J Med (1991) 1.23
The combined effect of perioperative donor spleen cells or KCl-extracted antigen and cyclosporine on renal allograft survival in the rat. Transplantation (1991) 1.02
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
Bone marrow as a potential source of hepatic oval cells. Science (1999) 8.52
Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92
Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54
Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01
Liver transplantation (1). N Engl J Med (1989) 4.53
Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32
Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29
Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18
Baboon-to-human liver transplantation. Lancet (1993) 4.01
The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet (1997) 3.70
Systemic chimerism in human female recipients of male livers. Lancet (1992) 3.63
Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63
Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57
Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. Transplant Proc (1987) 3.55
Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 3.43
Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med (1993) 3.36
Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34
Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29
Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant (2010) 3.29
Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26
The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol (1988) 3.24
Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18
Pathology of hepatic transplantation: A review of 62 adult allograft recipients immunosuppressed with a cyclosporine/steroid regimen. Am J Pathol (1985) 3.16
Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation (1993) 3.13
Orthotopic liver transplantation in dogs receiving FK-506. Transplant Proc (1987) 3.11
Age-related osteogenic potential of mesenchymal stromal stem cells from human vertebral bone marrow. J Bone Miner Res (1999) 3.05
Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med (1992) 2.98
Liver transplantation (2). N Engl J Med (1989) 2.93
Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res (1997) 2.91
Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91
The lost chord: microchimerism and allograft survival. Immunol Today (1996) 2.81
Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc (1993) 2.81
Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75
THE IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 IN RATS RECEIVING HETEROTOPIC CARDIAC ALLOGRAFTS. Surg Res Commun (1987) 2.75
Detection of Y chromosome sequences in Turner's syndrome by Southern blot analysis of amplified DNA. Lancet (1993) 2.65
A review of adult and pediatric post-transplant liver pathology. Pathol Annu (1987) 2.62
FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50
Propagation of dendritic cell progenitors from normal mouse liver using granulocyte/macrophage colony-stimulating factor and their maturational development in the presence of type-1 collagen. J Exp Med (1994) 2.48
Toxicology of FK-506 in the Lewis rat. Transplant Proc (1987) 2.37
Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31
FK 506 in clinical kidney transplantation. Transplant Proc (1991) 2.29
Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. Transplant Proc (1991) 2.28
Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transplant (2012) 2.28
Evidence for superantigen involvement in insulin-dependent diabetes mellitus aetiology. Nature (1994) 2.25
Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg (1995) 2.25
Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation (1992) 2.20
Transplantation milestones. Viewed with one- and two-way paradigms of tolerance. JAMA (1995) 2.20
Aspartic acid at position 57 of the HLA-DQ beta chain protects against type I diabetes: a family study. Proc Natl Acad Sci U S A (1988) 2.19
Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. Transplantation (1993) 2.17
Graft-versus-host disease after brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506. Transplantation (1993) 2.14
Modulation of nitrogen oxide synthesis in vivo: NG-monomethyl-L-arginine inhibits endotoxin-induced nitrate/nitrate biosynthesis while promoting hepatic damage. J Leukoc Biol (1990) 2.11
One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc (1991) 2.10
A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation (1995) 2.09
Shipment of human islets for transplantation. Am J Transplant (2007) 2.01
Results of our first nine intraportal islet allografts in type 1, insulin-dependent diabetic patients. Transplantation (1991) 1.98
Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation (1997) 1.98
Pathology of human intestinal transplantation. Gastroenterology (1996) 1.98
Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. Transplantation (1991) 1.95
NKR-P1, a signal transduction molecule on natural killer cells. Science (1990) 1.94
Successful hamster-to-rat liver xenotransplantation under FK506 immunosuppression induces unresponsiveness to hamster heart and skin. Transplantation (1993) 1.94
Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation (1999) 1.93
Lymphocyte traffic and graft-versus-host disease after fully allogeneic small bowel transplantation. Transplant Proc (1991) 1.89
Growth of donor-derived dendritic cells from the bone marrow of murine liver allograft recipients in response to granulocyte/macrophage colony-stimulating factor. J Exp Med (1995) 1.88
Improved human islet isolation using a new enzyme blend, liberase. Diabetes (1997) 1.84
Microchimerism, dendritic cell progenitors and transplantation tolerance. Stem Cells (1995) 1.83
The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. Transplantation (1992) 1.83
Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc Natl Acad Sci U S A (1999) 1.79
Early events in liver allograft rejection. Delineation of sites of simultaneous intragraft and recipient lymphoid tissue sensitization. Am J Pathol (1991) 1.78